What is cancer and what can we offer?

What is cancer and what can we offer?

Cancer is a class of diseases characterized by abnormal growth and distant spread of cells. There are more than 100 types of cancer that may differ by growth pattern, course of the disease, response to treatment and prognosis.

According to the cells of origin, cancers may be categorized as:

  • Carcinomas that are the most common type of cancer. They are formed by epithelial cells that cover the inside and outside surfaces of the body.
  • Sarcomas are tumours of the soft tissue, including muscle, fat, blood vessels, lymph vessels and fibrous tissue.
  • Leukaemia starts in the blood-forming tissue of the bone marrow.
  • Lymphomas are cancers of pathologically changed lymphocytes (the so called B and T cells).
  • Multiple myeloma is a cancer that begins in another type of immune cells – plasma cells.
  • Melanoma is a cancer of melanocytes that make melanin. Most melanomas develop in the skin, but they may also arise on other surfaces and organs. Some melanomas may be without pigmentation.
  • Brain and spinal cord tumours are of different types and may develop in the brain or in the spinal cord. These tumours may be both benign and malignant.
  • Other types of tumours include germ cell tumours, neuroendocrine tumours and carcinoid tumours.

How is cancer treated?

How is cancer treated?

Conventional primary methods of cancer treatment are:

  • Surgery.
  • Radiation therapy.
  • Chemotherapy.
  • Hormone therapy.
  • Immunotherapy.

What is cancer immunoherapy?

What is cancer biotherapy?

Immunotherapies are designed to boost the host’s immune system, either directly or indirectly. There are many types of immunotherapies like:

  • Non-specific immune-modulating agents.
  • Interferons.
  • Interleukins.
  • Colony-stimulating factors.
  • Monoclonal antibodies.
  • Vaccine therapies.
  • Oncolytic virotherapy.

The Global Virotherapy Cancer Clinic offers a unique possibility to treat cancer with an original oncolytic virus obtained almost 50 years ago. Rigvir® (ECHO-7) is officially registered for the treatment of melanoma, because it has been adapted to melanoma cells.

What is melanoma?

What is melanoma?

Melanoma is a type of cancer that starts in skin cells that give skin its colour. Melanoma can also form in the eyes, nose, mouth, genitalia, or, rarely, in the internal organs. 

Melanoma is more dangerous than most other common skin cancers because it is more likely to spread if it isn’t found early. Melanoma has the potential to spread through the dermis to nearby tissues and other parts of the body. The deeper a melanoma grows into the dermis, the higher the risk of spreading through lymph vessels or blood vessels.

There are four major types of cutaneous melanoma. Superficial spreading melanoma is the most common type of melanoma. It usually looks like a brown-black stain. Nodular melanoma grows more quickly deeper into the dermis than other types of melanoma. Lentigo maligna melanoma is the slowest growing type of melanoma. It tends to develop in sites of chronic sun exposure in older adults. Acral lentiginous melanoma is the least common type of melanoma. 

This type of melanoma is not related to UV light exposure. It occurs on the palms of the hands or soles of the feet, including fingernails and toenails.

Human melanomas are immunogenic. Virtually all the major principles of “tumour immunology” have been experimentally established in this model. Although these strategies have not been uniformly successful in all cases, durable complete regressions of metastatic melanoma can at times be obtained with immunotherapy.

Treatment of melanoma

There are many treatment options for melanoma. The type of treatment depends on a number of factors – the stage of the disease, sites of metastatic disease, the patient’s overall health condition, etc. However, supportive care is an important part of the overall treatment for all patients.

Melanomas could be treated locally (drugs could be inserted into the tumour or around it), or systemically (drugs could be delivered by intramuscular or intravenous injection).

Neoadjuvant treatment is given to shrink the tumour before surgery and to minimize the spread of melanoma cells during operation.

Primary treatment for melanoma is surgery – dissection of the melanoma (tumour) and the sentinel node.

Adjuvant treatment is usually given as a systemic treatment to eradicate any remaining melanoma cells after surgery.

Palliative treatment is the treatment of advanced, relapsed or metastatic melanoma.

Immunotherapy can be used both as a local therapy (interferon alfa, imiquimod, interleikin-2, T-VEC or ECHO-7) or a systemic therapy (interferon alfa. interleikin-2, ipilimumab, nivolumab, peginterferon alfa 2B, pembrolizumab and ECHO-7).

Targeted therapy drugs are designed to specifically target cancer cells. These drugs are used as systemic therapy (cobimetinib, dabrafenib, imatinib, trametenib, vemurafenib). All four of

these drugs except cobimetinib target tumours that have a damaged BRAF gene.

Chemotherapy is a type of drug commonly used to treat cancer, including melanoma (dacarbazine, cisplatin, paclitaxel, temozolomide, vinblastine). Many people refer to this treatment as “chemo.” Chemotherapy drugs kill fast-growing cells, including cancer cells and normal cells. Chemotherapy can be used as systemic therapy or regional therapy for melanoma, although it is not as effective as newer immunotherapies or targeted therapies. 

Stereotactic radiosurgery is a type of external beam radiation therapy that may be used for melanoma. This type of radiation therapy is most often used to treat melanoma that has spread to the brain—called brain metastases. SRS delivers a high dose of radiation to a very specific, small area of the body.

Rigvir for melanoma treatment

Rigvir for melanoma treatment

The best response is expected when used at early stages of the disease (neoadjuvant and adjuvant use). Rigvir® may be used either through a systemic administration intramuscularly, according to the regional principle of drug administration, or locally to bypass the tumour’s architectural barriers for locally advanced or locally recurrent melanoma and subcutaneous metastases.

After melanoma surgery, Rigvir® may postpone or even protect against further progression of the disease. For patients with metastatic melanoma, Rigvir® may slow down the course of the disease and improve their quality of life.

 

Becoming a patient

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper lobortisznulla facilisi.

Application form